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Abstract
Background: Considering previous data and the need to incorporate new biomarkers for the prognosis of solid
tumours into the clinic, our aim in this work consists of evaluating the potential clinical use of telomeres and
telomerase in non-small cell lung cancer (NSCLC).
Methods: Telomere status was established by determination of telomere length using the Terminal Restriction
Fragment length method, and telomerase activity by the Telomeric Repeat Amplification Protocol in 142 NSCLCs
and their corresponding control samples, obtained from patients submitted to surgery. Group-oriented curves for
disease-free survival were calculated according to the Kaplan-Meier method considering telomere length, T/N ratio
(telomere length in tumour to control tissue) and telomerase activity.
Results: Overall, tumours had significantly shorter telomeres compared with telomeres in control tissues (P = 0.027).
More than 80 % of NSCLCs displayed telomerase activity. Regarding prognosis studies, patients whose tumours
showed a mean telomere length (MTL) <7.29 Kb or T/N ratio <0.97 showed a significantly poor clinical
evolution (P = 0.034 and P = 0.040, respectively). As result of a Cox multivariate analysis including pathologic
state and lymph node dissemination, the MTL and T/N ratio emerged as independent significant prognostic
factors.
Conclusions: Telomerase activity was identified as a marker of poor prognosis. The novel finding of this
study is the independent prognosis role of a specific telomere status in NSCLC patients. According to our
results, telomere function may emerge as a useful molecular tool that allow to select groups of NSCLC
patients with different clinical evolution, in order to establish personalized therapy protocols.
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Background
Lung cancer remains the most common cancer in men
worldwide [1] and the identification of subjects at higher
risk of cancer progression and recurrence, who would
benefit from more specific therapies, is necessary [2].
The risk assessment by the Tumour-Nodes-Metastasis
(TNM) staging system is relatively inexact as it only con-
siders tumour characteristics at a particular moment
(TNM at diagnosis) [3]. Of fundamental concern is the
identification and use of new biomarkers, with high spe-
cificity and sensitivity, which will allow the prediction of
the disease course and identification of patients who
would or would not benefit from specific therapy. In this
way, telomere function has been recognized as possible
biomarker [2]. However, it has not yet been established a
consensus for the use of telomere function in cancer
clinical practice.
Telomeres are ribonucleoprotein complexes located
at the ends of eukaryotic chromosomes which consist
of tandem repeats of a DNA sequence (TTAGGG in all
vertebrates) [4]. Among its main functions, telomeres
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mask double strand break DNA damage signals at the ex-
treme of chromosome and prevent chromosomal fusions
[5–8]. In the context of a somatic cell, a significant telo-
mere shortening is monitored by p53 and RB1 and leads
to cell death or senescence. However, cells that surpass
their normal replicative limit and continue to divide lose
all remaining protective telomeric DNA and enter the cri-
sis stage, characterised by massive genomic instability and
cell death [9]. At this point, transformed clones emerge
and telomerase activation is detectable in the majority of
tumour cells and is the main positive power for telomere
preservation and elongation [10].
Telomeres and telomerase play a crucial role in human
carcinogenesis: the majority of tumours have telomere
length alterations which can eventually lead to telomere
dysfunction [11]. A disruption of telomere length
homeostasis affects telomere structure and leads to gen-
omic instability by generating chromosome end-to end
fusions and chromosomal abnormalities [5]. In relation
to telomerase, an increase in telomerase activity is often
directly correlated with uncontrolled growth of cells, a
known hallmark of cancer, and has become a widely ac-
ceptable tumour marker and a popular target for anti-
cancer therapeutics [12].
Considering previous data and the need to incorporate
new biomarkers for the prognosis of solid tumours into
the clinic, our first aim in this work consists of evaluat-
ing the potential clinical use of telomeres and telomerase
in NSCLC. With this objective, we analyzed both param-
eters directly implicated in telomere function in a large
series of cases of NSCLC. Thus, we identified groups of
NSCLC patients with different clinical evolution, inde-
pendently of the TNM stage tumours, in relation to telo-
mere status (telomere length & T/N ratio).
Methods
Patients and tissue samples
One hundred and forty-two primary NSCLCs were ob-
tained from patients who had undergone potentially
curative surgery at San Carlos Hospital in Madrid, Spain.
Paired non-tumour tissues from the same patient, used
as controls, were obtained and microscopically con-
firmed. After surgical resection, all tissue samples were
snap-frozen in liquid nitrogen and stored at −80 °C until
processed. Cryostat sectioned, H&E stained samples
from each tumour block were examined microscopically
by two independent pathologists to confirm the presence
of ≥80 % tumour cells. All the cases were collected with-
out selection in function of gender, age or tumour stage
and no patient had received previous chemotherapy or
radiotherapy before diagnosis and entry into this study.
Informed consent was obtained from patients prior to
investigation and this study was approved by the Ethical
Committee of the Hospital.
NSCLCs were staged pathologically using the TNM sys-
tem 6th Edition [13] and consisted of 86 TNM I tumours,
9 TNM II tumours, 38 TNM IIIA tumours, 5 TNM IIIB
tumours and 4 TNM IV tumours. The median follow-up
period of patients was 5 years (range, 1–133 months).
Telomere length measurement
Terminal Restriction Fragment (TRF) length measure-
ment was performed using Telo TTAGGG Telomere
Length Assay kit (Roche Applied Science, Germany) as
previously described [14]. TRF lengths for tumour and
control tissues were determined by comparing the sig-
nals relative to a standard molecular weight using Image
Gauge software (version 3.46; Fujifilm, Japan). The TRF
length ratio was determined as the ratio of the length of
tumour tissue TRF and their paired normal tissue TRF
(T/N ratio).
Telomerase activity determination
Telomerase activity was measured using the Telomeric
Repeat Amplification protocol (TRAP)-based telomerase
polymerase chain reaction (PCR)-enzyme-linked im-
munosorbent assay (ELISA) kit (Roche Applied Science,
Germany), as described earlier [15]. Considering that the
cut-off for TRAP-ELISA negativity corresponds to an
optical density (OD) 450 nm < 0.2, all samples with OD
450 nm ≥ 0.2 were considered telomerase positive [15].
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware package (version 19.0 SPSS, Chicago, IL, USA). Dif-
ferences in telomere length and T/N ratio among various
groups of patients, discriminated for clinical variables,
were analysed by the Student-T and ANOVA tests, or
their non-parametric alternatives, Mann-Whitney U test
and Kruskal-Wallis test. P-value < 0.05 was considered sta-
tistically significant. The paired samples T test was used
for comparing the means of two related variables.
Group-oriented curves for disease-free survival (DFS)
were calculated according to the Kaplan-Meier method
considering telomere length, T/N ratio and telomerase
activity. DFS was calculated from the day of surgery until
recurrence. The differences in DFS across different
groups were compared using the log-rank test. The rela-
tive prognostic impact of telomere length, T/N ratio and
telomerase activity, compared with established prognosis
factors, was analysed using Cox multivariate analysis.
Cutoff Finder Web Application [16] was used to deter-
mine the cut-off points for prognosis analysis.
Results
Telomere status and telomerase activity in tissue samples
We evaluated telomere length in a total of 284 lung tissue
samples: 142 NSCLCs and the corresponding non-tumour
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samples. The mean telomere length (mean ± standard
error) was 6.56 ± 0.26 Kb in NSCLCs and 7.00 ± 0.19 Kb
for non-tumour samples. Overall, tumours had signifi-
cantly shorter telomeres than matched non-tumour
tissues (P = 0.027; paired T test). The T/N ratio was
0.93 ± 0.026. Positive results for telomerase activity
were found in 123 (86.6 %) of 142 NSCLCs; 19 tumours
(13.4 %) were telomerase negative.
Telomere status and telomerase activity: correlation with
clinical variables of non-small cell lung tumours
As it is showed in the Table 1, there was a statistically sig-
nificant association between the telomere length and the
size of the primary tumour (T), (P = 0.006; Kruskal-Wallis
test): T1 tumours had shorter telomeres than both T2 and
T3 tumours. T4 tumours, comprised of a limited number
of cases, had a mean telomere length close to T1 tumours.
Moreover, there were significant differences between the
T/N ratio and T descriptor (P = 0.024; Kruskal-Wallis test).
A significant association was found between the tumour
histology and the T/N ratio (P = 0.022; Kruskal-Wallis test),
which was significantly diminished in large cell undifferen-
tiated carcinomas compared to squamous cell carcinomas
and adenocarcinomas. No association was found neither to
telomere length nor T/N ratio for the gender, TNM stage,
lymph node dissemination (N) and tumour metastasis (M)
in NSCLCs (Table 1).
Finally, applying a Chi-square test a statistical asso-
ciation between telomerase activity and the gender
(P = 0.034), TNM stage (P = 0.042), tumour metastasis
(P = 0.029) and tumour histology (P = 0.019) was found
(Table 2).
Table 1 Telomere status and clinical variables in non-small cell lung cancers
Variable N° of
cases
Telomere length P and test statistic T/N ratio P and test statistic
(Kilobase pairs;
mean ± standard error)
(mean ± standard error)
Gender 142
Female 12 5.49 ± 0.69 0.274; Mann-Whitney U Test 0.83 ± 0.07 0.416; Mann-Whitney U Test
Male 130 6.66 ± 0.28 0.94 ± 0.03
TNM stage 142
I 86 6.08 ± 0.29 0.204; one-way ANOVA 0.91 ± 0.03 0.442; Kruskal-Wallis test
II 9 7.01 ± 1.37 0.96 ± 0.11
IIIA 38 7.45 ± 0.57 1.00 ± 0.06
IIIB 5 6.15 ± 1.55 0.85 ± 0.18
IV 4 7.79 ± 2.84 0.80 ± 0.10
Size of the primary tumour, T 142
T1 22 5.54 ± 0.52 0.006; Kruskal-Wallis test 0.93 ± 0.04 0.024; Kruskal-Wallis test
T2 91 6.32 ± 0.30 0.90 ± 0.03
T3 22 8.84 ± 0.84 1.11 ± 0.09
T4 7 5.75 ± 1.10 0.79 ± 0.13
Lymph node dissemination, N 142
N0 102 6.44 ± 0.30 0.532; Kruskal-Wallis test 0.93 ± 0.03 0.456; Kruskal-Wallis test
N1 11 7.74 ± 1.22 1.02 ± 0.10
N2 28 6.64 ± 0.62 0.93 ± 0.07
N3 1 3.25 0.62
Tumour metastasis, M 142
Absence, M0 138 6.52 ± 0.26 0.848; Mann-Whitney U Test 0.94 ± 0.03 0.349; Mann-Whitney U Test
Presence, M1 4 7.79 ± 2.84 0.80 ± 0.10
Histology 141a
Squamous cell carcinoma
(SCC)
79 6.47 ± 0.33 0.128; Kruskal-Wallis test 0.94 ± 0.03 0.022; Kruskal-Wallis test
Adenocarcinoma (AD) 56 6.93 ± 0.46 0.96 ± 0.04
Large cell undifferentiated
carcinoma (LCUC)
6 4.31 ± 0.89 0.64 ± 0.10
aMissing data
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Considering our studied population, no significant dif-
ferences were found between the telomere lengths of
negative and positive telomerase activity tumours
(P = 0.549; Mann-Whitney U test). The mean telomere
length (mean ± typical error) was 7.16 ± 0.87 Kb in nega-
tive telomerase activity tumours and 6.47 ± 0.27 Kb, for
positive telomerase activity tumours. The range of tumour
telomere lengths between the groups defined by telomer-
ase activity was similar: 1.51–16.49 Kb for negative tel-
omerase activity tumours and 1.42–17.50 Kb for positive
telomerase activity tumours.
Telomere status, telomerase activity and NSCLC patients
prognosis
Prognosis studies were developed to assess the impact on
clinical course of telomere status (telomere length & T/N
ratio) and telomerase activity in patients with resected
NSCLCs. Only patients who had undergone potentially
curative surgery and who did not die during the post-
operatory period were considered in these studies, as
established in the literature. A total of 125 cases were con-
sidered. First, patients were stratified into two groups ac-
cording to the mean telomere length using the Cutoff
Finder Web Application [16]: the group of patients who
had tumours with a mean telomere length <7.29 Kb pre-
sented a significantly poor clinical evolution, compared to
the group whose mean tumour telomere length was >7.29
Kb (P = 0.034; Log-Rank. Fig. 1a). Forty percent (32/80) of
patients included in the first group relapsed during the
follow-up period, compared with the second group where
20 % of patients (9/45) experienced a relapse. The Kaplan-
Meier curves show this relationship between the telomere
length and disease-free survival (Fig. 1a).
Next, using the Cutoff Finder Web Application [16]
the best prognostic cut-off for the T/N ratio was set in
0.97: patients who had tumours with a T/N ratio
Table 2 Telomerase activity and clinical variables in non-small cell lung cancers
Variable N° of cases Telomerase activity P; Chi-square test
Negative Positive
Gender 142
Female 12 4 8
0.034
Male 130 15 115
TNM stage 142
I 86 12 74
0.042
II 9 1 8
IIIA 38 2 36
IIIB 5 2 3
IV 4 2 2
Size of the primary tumour, T 142
T1 22 3 19
0.126
T2 91 11 80
T3 22 2 20
T4 7 3 4
Lymph node dissemination, N 142
N0 102 13 89
0.838
N1 11 1 10
N2 28 5 23
N3 1 0 1
Tumour metastasis, M 142
Absence, M0 138 17 121
0.029
Presence, M1 4 2 2
Histology 141a
Squamous cell carcinoma (SCC) 79 8 71
0.019Adenocarcinoma (AD) 56 7 49
Large cell undifferentiated carcinoma (LCUC) 6 3 3
aMissing data
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<0.97 had a significantly shorter disease-free survival
compared with patients who had a bigger T/N ratio
(P = 0.040; Log-Rank. Fig. 1b).
As result of a Cox multivariate analysis, including
TNM stage and lymph node dissemination (only these
factors had prognostic relevance in the univariate ana-
lysis, P < 0.001), telomere length emerged as an inde-
pendent significant prognostic factor (Table 3A and B).
In both cases, the patients with a mean telomere length
<7.29 Kb were at increased risk for recurrence. Also
using the Cox multivariate analysis, a mean T/N ratio
<0.97 was found to be a prognostic factor independent
of the TNM stage (P = 0.041) (Table 4A and B).
Finally, telomerase activity discriminated between
two groups of patients: the absence of telomerase ac-
tivity in the tumour conferred a better clinical evolu-
tion (P = 0.039; Log-Rank. Fig. 2). In multivariate
analysis, a clear trend towards a potential role for tel-
omerase activity as an independent prognostic factor
of the TNM stage (P = 0.089) and lymph node dissem-
ination (P = 0.101) was found.
Discussion
Malignant cells, in general, have shorter telomeres than
their normal counterparts [17] as a reflection of their ex-
tended proliferation. In fact, diseases of high cellular turn-
over are associated with telomere shortening, telomere
dysfunction and cancer predisposition [18]. In bronchial
carcinogenesis, telomere shortening is an early event [19]
and previous results [20] including those of our research
group [15] show a significant telomere shortening in
NSCLCs in relation to the control tissues. In other tumour
types, telomere attrition has been also demonstrated [21].
Therefore, the results shown in this paper, as with the pre-
vious data, reflect differences between the mean telomere
length in NSCLCs and the non-tumour tissues, which are
validated by a T/N ratio <1.
Progressive telomere erosion is countered with tel-
omerase, which is expressed in the vast majority of hu-
man cancers [12]. Our data indicated more than 80 % of
NSCLCs analysed expressed telomerase activity, in agree-
ment with previously published works [15], without sig-
nificant differences in the mean telomere length values
between telomerase positive and negative tumours. Al-
though telomerase activation can be an early event in can-
cer, it is not necessary for cancer initiation. However,
Fig. 1 Kaplan-Meier plots of Disease Free Survival (DFS) considering telomere status. Kaplan-Meier survival curves in relation to telomere length (a) and
T/N ratio (b) in non-small cell lung cancer. Numbers in brackets represent cases with tumour recurrence and crosses indicate censored data
Table 3 Multivariate Cox Regression Analysis considering TNM
stage (A), lymph node dissemination (B) and telomere length
for 125 patients with non-small cell lung cancer
(A) Variable HR (95 % CI) P
Mean telomere length in
NSCLCs <7.29 Kb
2.70 (1.27–5.76) 0.010
TNM stage, I vs. II or IIIA 0.34 (0.17–0.67) 0.002
(B) Variable RR (95 % CI) P
Mean telomere length in
NSCLCs <7.29 Kb
2.26 (1.07–4.76) 0.032
Lymph node dissemination (N),
negative (N0) vs. positive (N1 or N2)
0.41 (0.19–0.88) 0.021
HR hazard ratio, CI confidence interval
Table 4 Multivariate Cox Regression Analysis considering TNM
stage (A), lymph node dissemination (B) and T/N ratio for 125
patients with non-small cell lung cancer
(A) Variable HR (95 % CI) P
Mean T/N ratio <0.97 2.02 (1.03–3.97) 0.041
TNM stage, I vs. II or IIIA 0.42 (0.21–0.81) 0.010
(B) Variable RR (95 % CI) P
Mean T/N ratio <0.97 1.93 (0.98–3.81) 0.058
Lymph node dissemination (N),
negative (N0) vs. positive (N1 or N2)
0.44 (0.21–0.95) 0.036
HR hazard ratio, CI confidence interval
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telomerase can stimulate tumour progression by ensuring
maintenance of telomeres above a critically short length,
thus preventing induction of cellular senescence or apop-
tosis [22]. Appart from telomerase, possible implication of
Alternative Lengthening of Telomeres (ALT) mechanisms
in telomere elongation of telomerase-negative tumours
should be considered. However, the ALT phenotype was
not investigated in our research work considering the lim-
ited role of this mechanism in lung cancer. In fact, the
ALT phenotype is common in tumours such as osteosar-
comas, undifferentiated pleomorphic sarcomas, leio-
myosarcomas, astrocytic tumours grades 2 and 3, and
pancreatic neuroendocrine tumours [11, 23]. However,
ALT is a very infrequent mechanism in the most
common cancer types, carcinomas, which are derived
from epithelia [24]. Heaphy et al. assessed the ALT
phenotype in 6110 primary tumours from 94 different
cancer subtypes and this mechanism was not detected
in most lung carcinoma subtypes, only individual
cases of small cell (2 %) and large cell lung carcin-
omas (3 %) were observed. ALT-positive cells are
characterized by striking telomere length heterogen-
eity [11]. In the present work, it is noteworthy that
the maximum value in telomere length for telomerase
positive and negative lung tumours is close to that
defined in the normal human population: the length
of telomeres is heterogeneous, ranging between 5 and
15 Kb [25]. Therefore, very long telomeres, other fea-
ture of ALT, were not detected.
The role of telomeres in the initiation and progression
of carcinogenesis has been widely recognized [11]; thus,
its relation with clinical variables, in conjunction with
others molecular markers, could represent a therapeutic
opportunity for cancer patients. Currently, except for re-
cent developments in relation to the involvement of
EGFR mutational status [26], limited advances in the de-
tection of molecular targets in lung cancer were ob-
tained. For NSCLCs, the statistical association between
the tumour size (T descriptor) and telomere status is in
line with previously published data [15]: the highest de-
gree of telomere shortening is detected for tumours that
grow into the area of mediastinum or cancers in which a
malignant pleural effusion is reached (T4).
An altered telomere length in cancer cells could give
the ability to metastasize and cause recurrent disease
and, in consequence, be a predictor of clinical outcome.
Previous works concluded that careful assessment of
telomere length or its proxies, such as DNA content, will
be part of novel risk assessment and prognostic modal-
ities for patients [2]. More recently, in glioblastoma
multiform tumours, telomeres were always shorter when
compared with normal brain tissue, and together with
telomerase activity seem to be associated with malig-
nancy and poor outcome [27]. In lung cancer, previous
studies have evaluated whether telomere length could
represent a risk factor or a prognostic marker, however
most of them are contradictory: for NSCLCs patients
both shorter and longer telomeres has been associated
with decreased overall survival [28]. Results obtained in
the present work indicate that the worst prognosis is
seen in patients whose mean tumour telomere length is
lower than 7.29 Kb or when almost any degree of telo-
mere shortening is reached in tumours cells. Both pa-
rameters related to telomere status proved to be
independent of other known prognostic factors. How-
ever, we also demonstrated in colorectal cancer that
telomere attrition conferred good clinical evolution.
Therefore, cancer prognosis associated to telomere sta-
tus could be dependent on the tumour type [14]. A de-
ficiency in the function of senescence and cell death
pathways [29], or other molecules related to telomere
maintenance and genome instability [30] could explain
the unfavorable prognosis for post-surgical patients
with NSCLCs and short telomeres. Genetic context
underlying telomere status, which confers the different
clinical outcome, must be carefully considered.
Recently, two works have demonstrated that leukocyte
relative telomere length in peripheral blood is an inde-
pendent prognostic marker in glioma and gastric cancer
patients, being shorter telomeres associated with the worst
clinical evolution of patients [31, 32]. Telomere analyses
in leukocytes from peripheral blood could be a useful bio-
marker to improve the prognosis prediction in cancer
Fig. 2 Kaplan-Meier plots of Disease Free Survival (DFS)
considering telomerase activity. Kaplan-Meier survival curves in
relation to telomerase activity. Numbers in brackets represent
cases with tumour recurrence and crosses indicate censored data
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patients. However, previously it is necessary corroborate
and validate correlations between telomere status in blood
cells and tumours through prospective studies. This is a
field that needs to be investigated in lung cancer.
Finally, the presence of telomerase activity in NSCLCs
conferred the worst outcome, confirming previous re-
sults [15]. Telomerase activity or hTERT expression has
proved to be a marker of malignancy. Furthermore, its
diagnostic utility is being demonstrated [11].
Conclusions
The novel finding of this study is the independent
prognosis role of a specific telomere status in NSCLC
patients. Moreover, telomerase activity is confirmed as
a prognostic marker in NSCLC. According to results
from the present work, telomere function may emerge
as a useful molecular tool that allow to select groups
of NSCLC patients with different clinical evolution, in
order to establish personalized therapy protocols.
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